8th Jul 2014 10:50
LONDON (Alliance News) - AstraZeneca PLC said Tuesday that it has agreed with the Max Planck Institute of Molecular Physiology in Germany to establish a new unit to study new modalities chemistry.
The new unit will be linked to AstraZeneca's CVMD Innovative Medicines unit in Sweden. AstraZeneca will work with researchers from Max Planck to focus on novel chemistry and chemical biology in areas of new modality chemistry like stabilised peptides, macrocycles and conjugation chemistry.
Shares in AstraZeneca were trading up 0.9% at 4,410.46 pence Tuesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca